AGIO
NASDAQAgios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc. (AGIO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for AGIO, including 3 press releases and news items, 2 insider trades and 2 SEC filings. The most recent was published Nov 5, 2026.
AGIO rankings
Financial highlights
Full financials- Revenue, TTM
- $140.84M
- Revenue growth
- +214.4%
- Net income, TTM
- -$372.90M
- Net margin
- -264.8%
- Free cash flow, TTM
- -$335.97M
- Cash
- $128.55M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks47+200%
2026-05-172026-11-08
Mix1290d
- Other5(42%)
- Earnings2(17%)
- Insider2(17%)
- SEC Filings2(17%)
- Analyst1(8%)
Activity · 52 weeks10150 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Agios Pharmaceuticals Inc.10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- SECAgios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- PRAgios Reports Third Quarter 2026 Financial Results and Provides Business UpdateMitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025Strong U.S. demand for AQVESME in thalassemia continues, with 619 cumulative prescriptions with completed start forms from REMS-certified physicians, plus 48 additional prescriptions with start forms in process as of September 30, 2026 New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA14 abstracts accepted at ASH 2026, including new clinical data for mitapivat in sickle cell disease and for AG-236 in polycythemia vera,
- PRAgios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 202614 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show durable hemoglobin improvements for up to two years, as well as potential kidney and cardiac health benefits First AG-236 clinical data from Phase 1 trial in healthy volunteers support every-six-month dosing in polycythemia vera, supporting a potential best-in-class profile Agios will host ASH 2026 virtual investor event on Monday, December 14, at 1:00 p.m. EST (12:00 p.m. CST) CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a co
- PRAgios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDAFDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell diseaseFDA classified Agios’ response to the information request as a major amendment to the mitapivat sNDA, resulting in a three-month review extensionMitapivat sNDA was submitted under the FDA’s accelerated approval pathway and granted Priority Review, with an original PDUFA goal date of November 1, 2026Agios will continue its labeling discussions with the FDA as part of the ongoing sNDA review, including elements of a potential REMS CAMBRIDGE, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company fo
- ANALYSTH.C. Wainwright resumed coverage on Agios Pharma with a new price targetH.C. Wainwright resumed coverage of Agios Pharma with a rating of Buy and set a new price target of $55.00
- INSIDERChief Medical Officer Gheuens Sarah sold $296,470 worth of shares (7,866 units at $37.69) as part of a pre-agreed trading plan (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERChief Medical Officer Gheuens Sarah sold $74,642 worth of shares (1,989 units at $37.53) as part of a pre-agreed trading plan (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRA Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayNEW YORK, Oct. 20, 2026 /CNW/ -- Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare light-sensitivity disorder reported that its pivotal Phase 3 trial met every primary and secondary endpoint, and its shares rose 38.86%. The same day, a developer of an RNA-based therapy for a rare blood disorder agreed to be acquired at a 130% premium, and its shares more than doubled. Several other companies working on rare blood and iron-metabolism disorders also moved higher, according to Stock Analysis data. Active Companies from around the markets with current developments this week inc
- PRAgios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ETCAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m. ET to report its third quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections
- FDAFDA Approval for PYRUKYND issued to AGIOS PHARMS INCSubmission status for AGIOS PHARMS INC's drug PYRUKYND (SUPPL-7) with active ingredient MITAPIVAT SULFATE has changed to 'Approval' on 09/28/2026. Application Category: NDA, Application Number: 216196, Application Classification: Manufacturing (CMC)
- FDAFDA Approval for AQVESME issued to AGIOS PHARMS INCSubmission status for AGIOS PHARMS INC's drug AQVESME (SUPPL-7) with active ingredient MITAPIVAT SULFATE has changed to 'Approval' on 09/28/2026. Application Category: NDA, Application Number: 216196, Application Classification: Manufacturing (CMC)
- INSIDERChief Medical Officer Gheuens Sarah sold $914,400 worth of shares (30,000 units at $30.48) as part of a pre-agreed trading plan, decreasing direct ownership by 35% to 54,645 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Agios Pharmaceuticals Inc.SCHEDULE 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
- SECSEC Form 10-Q filed by Agios Pharmaceuticals Inc.10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- SECAgios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- PRAgios Reports Second Quarter 2026 Financial Results and Provides Business UpdateMitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopenia and advancement of AG-236 into Phase 2/3 development for polycythemia vera $964.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026; well capitalized to support comme
- PRAgios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell DiseaseHemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell diseaseSafety and tolerability of tebapivat were consistent with prior sickle cell disease trialssNDA for mitapivat, company’s foundational PK activator, is under FDA Priority Review in sickle cell disease; PDUFA goal date is November 1, 2026 CAMBRIDGE, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced topline re
- INSIDERDirector Backstrom Jay T. was granted 1,447 shares (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRU.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell DiseaseFDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA’s accelera
- SECSEC Form SCHEDULE 13G filed by Agios Pharmaceuticals Inc.SCHEDULE 13G - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
- INSIDERChief Medical Officer Gheuens Sarah sold $150,503 worth of shares (4,007 units at $37.56) as part of a pre-agreed trading plan and converted options into 8,375 shares, increasing direct ownership by 5% to 84,645 units (SEC Form 4) to cover withholding tax4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRAgios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ETCAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections t
- INSIDERDirector Ballal Rahul D. converted options into 2,816 shares, increasing direct ownership by 23% to 15,230 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Capello Jeffrey D converted options into 2,816 shares, increasing direct ownership by 35% to 10,865 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
AGIO FAQ
11 questionsWhat does Agios Pharmaceuticals Inc. do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat...What is the latest news on AGIO?
In the last 30 days Quantisnow tracked 9 wire items for AGIO: 3 press releases and news items, 2 insider trades, 2 SEC filings and 1 analyst rating. The most recent was published on November 5, 2026.What is AGIO revenue?
Agios Pharmaceuticals Inc. (AGIO) reported $140.84M of revenue for the twelve months ended Sep 30, 2026. That is up 214.4% from the year before. Revenue for fiscal 2025 was $54.03M.Is AGIO profitable?
No. Agios Pharmaceuticals Inc. reported a net loss of $372.90M for the twelve months ended Sep 30, 2026.How much cash and debt does AGIO have?
Agios Pharmaceuticals Inc. reported $128.55M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does AGIO stock trade?
Agios Pharmaceuticals Inc. (AGIO) is listed on NASDAQ.What sector and industry is AGIO in?
Agios Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Agios Pharmaceuticals Inc. go public?
Agios Pharmaceuticals Inc. (AGIO) completed its IPO in 2013.What are analysts saying about AGIO?
Across the last 8 analyst actions on Agios Pharmaceuticals Inc., there were 1 upgrade and 1 downgrade. The most recent action was from H.C. Wainwright: Buy with a $55.00 price target on 2026-10-29. Recent price targets range from $28.00 to $58.00.What companies are similar to AGIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AGIO side-by-side with any of them on Quantisnow.How can I track AGIO on Quantisnow?
Quantisnow aggregates Agios Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AGIO to receive live email and push alerts on every new disclosure.